简化PromisE分型在子宫内膜癌中的临床病理特征及预后分析OA
Clinical and pathological features and prognostic analysis of endometrial cancer with simplified PromisE classification
目的 探讨简化 PromisE 分型在子宫内膜癌(endometrial cancer,EC)中的临床病理特征及其对治疗和预后的影响.方法 收集90 例子宫内膜癌患者的临床资料,根据 MMR 和 p53 免疫组化结果定义简化 PromisE 分型,将患者分为四种分子亚型:MMRp/p53wt,MMRd/p53wt,MMRp/p53abn,MMRd/p53abn,分析四组患者的临床病理特征及其预后情况.结果 四组 EC 分子亚型的组织学类型、肿瘤分级、肌层浸润深度、雌激素受体/孕激素受体表达及淋巴脉管间隙浸润比较,差异有统计学意义(P<0.05).四条生存曲线比较,差异有统计学意义(P<0.05),其中,MMRp/p53wt 组预后最好,MMRd/p53abn 组预后最差.COX 回归单因素分析表明,FIGO 分期、肌层浸润深度及分子分组与 EC 患者的总生存时间有关(P<0.05).多因素分析表明,FIGO 分期是影响 EC 患者预后的独立危险因子(P<0.05).结论 简化PromisE 分型对评估子宫内膜癌的临床病理特征和预后有一定的指导作用.
Objective To explore the clinical pathological characteristics of simplified PromisE classification in endometrial carcinoma(EC)and its impact on treatment and prognosis.Methods The clinical data of 90 patients with endometrial cancer were collected.Based on the immunohistochemistry results of mismatch repair(MMR)and p53,the simplified PromisE classifi-cation was defined,and patients were divided into four molecular subtypes:MMRp/p53wt,MMRd/p53wt,MMRp/p53abn,and MMRd/p53abn.The clinical pathological characteristics and prognosis of the four groups were analyzed.Results Significant differences were observed in histological type,tumor grade,myometrial invasion,estrogen receptor(ER)/progesterone receptor(PR)expression,and lymphovascular space invasion(LVSI)among the four EC molecular subtypes(P<0.05).The compari-son of four survival curves showed significant differences(P<0.05),with the MMRp/p53wt group having the best prognosis and the MMRd/p53abn group having the worst.Univariate Cox regression analysis revealed that FIGO stage,myometrial invasion,and molecular grouping were associated with overall survival time in EC patients(P<0.05).Multivariate analysis identified FI-GO stage as an independent risk factor affecting the prognosis of EC patients(P<0.05).Conclusion The simplified PromisE classification has a certain guiding role in evaluating the clinical and pathological features and prognosis of endometrial cancer.
赵晓南;常文丽;王秀献;崔光轩;李丽
山东医药大学附属医院妇产科 山东 滨州 256603山东医药大学附属医院病理科 山东 滨州 256603山东医药大学附属医院妇产科 山东 滨州 256603山东医药大学第一临床医学院 山东 滨州 256603山东医药大学附属医院妇产科 山东 滨州 256603
医药卫生
子宫内膜癌分子分型错配修复蛋白p53预后治疗
endometrial cancermolecular typingmismatch repair proteinp53prognosistreatment
《滨州医学院学报》 2026 (4)
370-374,5
滨州医学院大学生创新创业训练计划(X202310440336)
评论